GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (FRA:NXOA) » Definitions » Gross Margin %

Nicox (FRA:NXOA) Gross Margin % : 0.00% (As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Nicox Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Nicox's Gross Profit for the six months ended in Jun. 2024 was €6.07 Mil. Nicox's Revenue for the six months ended in Jun. 2024 was €6.07 Mil. Therefore, Nicox's Gross Margin % for the quarter that ended in Jun. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Nicox's Gross Margin % or its related term are showing as below:

FRA:NXOA' s Gross Margin % Range Over the Past 10 Years
Min: -245.35   Med: 63.99   Max: 89.49
Current: -176.95


During the past 13 years, the highest Gross Margin % of Nicox was 89.49%. The lowest was -245.35%. And the median was 63.99%.

FRA:NXOA's Gross Margin % is ranked worse than
97.18% of 746 companies
in the Biotechnology industry
Industry Median: 59.475 vs FRA:NXOA: -176.95

Nicox had a gross margin of N/A% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Nicox was 0.00% per year.


Nicox Gross Margin % Historical Data

The historical data trend for Nicox's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Gross Margin % Chart

Nicox Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 82.99 89.49 84.27 -245.35 -176.95

Nicox Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.58 -489.42 - - -

Competitive Comparison of Nicox's Gross Margin %

For the Biotechnology subindustry, Nicox's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nicox's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Nicox's Gross Margin % falls into.


;
;

Nicox Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Nicox's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-11.8 / 6.646
=(Revenue - Cost of Goods Sold) / Revenue
=(6.646 - 18.406) / 6.646
=-176.95 %

Nicox's Gross Margin for the quarter that ended in Jun. 2024 is calculated as


Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=6.1 / 6.069
=(Revenue - Cost of Goods Sold) / Revenue
=(6.069 - 0) / 6.069
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Nicox  (FRA:NXOA) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Nicox had a gross margin of N/A% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Nicox Gross Margin % Related Terms

Thank you for viewing the detailed overview of Nicox's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nicox Business Description

Traded in Other Exchanges
Address
Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

Nicox Headlines

No Headlines